Amylyx is a cash-burning, pre-revenue biotech with a quality score of 1.6/10 and a single-asset pipeline, offset by 28.5% upside to the analyst target and constructive price momentum ahead of earnings in 4 days.
Thesis pillars
- Single Asset Pipeline Concentration↓Deteriorating
- Cash Burning Low Quality→Stable
- Analyst Target Upside→Stable
- +2 more pillars — see the Why tab for full reasoning
Pillars as of Nov 1, 2026, based on the 10-K filed Mar 3, 2026
Amylyx Pharmaceuticals, Inc. (AMLX) Stock Analysis
Healthcare · Drug Manufacturers - Specialty & Generic
Sell if holding. Engine safety override at $29.40: a dimension score below its floor triggers a hard block regardless of the otherwise-positive setup — overall score 5.2/10 and A.R:R 2.3:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 13%; Elevated put/call ratio: 1.82; Below-average business quality.
Amylyx Pharmaceuticals is a clinical-stage company with no currently approved products, advancing therapies in endocrine and neurodegenerative diseases. The lead asset avexitide, a GLP-1 receptor antagonist for post-bariatric hypoglycemia, is in Phase 3 (LUCIDITY) with topline... Read more
Sell if holding. Engine safety override at $29.40: a dimension score below its floor triggers a hard block regardless of the otherwise-positive setup — overall score 5.2/10 and A.R:R 2.3:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 13%; Elevated put/call ratio: 1.82; Below-average business quality. Chart setup: No clear chart pattern; technical signals are mixed. Score 5.2/10, moderate confidence.
Passes 8/8 gates (positive momentum, favorable risk/reward ratio, clean insider activity, no SEC red flags, news events none recent, earnings proximity no date, semi cycle peak clear, materials cycle peak clear). Suitability: aggressive.
About Amylyx Pharmaceuticals, Inc.
About Amylyx Pharmaceuticals, Inc.
Amylyx Pharmaceuticals is advancing avexitide through the 75-participant Phase 3 LUCIDITY trial for post-bariatric hypoglycemia, with topline data expected in Q3 2026 and a commercial launch targeted for 2027 if the FDA approves. The company accumulated a $751.4 million deficit through December 31, 2025—following the 2024 voluntary market withdrawal of RELYVRIO/ALBRIOZA for ALS after the Phase 3 PHOENIX trial failed its primary and secondary endpoints—down from $380.8 million in RELYVRIO revenue generated in 2023.
Amylyx generates no product revenue following the withdrawal of RELYVRIO/ALBRIOZA; future revenue depends on regulatory approval and successful commercialization of pipeline assets. Avexitide targets post-bariatric hypoglycemia (PBH), estimated to affect roughly 8% of U.S. patients who have undergone the two most common bariatric surgeries—approximately 160,000 people in the U.S. The FDA granted avexitide Breakthrough Therapy Designation for both PBH and congenital hyperinsulinism, Rare Pediatric Disease Designation for congenital HI, and Orphan Drug Designation for hyperinsulinemic hypoglycemia. Manufacturing of all pipeline assets—avexitide, AMX0035, AMX0114, and AMX0318—is entirely outsourced to third-party CMOs; the company has no internal manufacturing capability. AMX0035, an oral fixed-dose combination of sodium phenylbutyrate and taurursodiol, is in open-label Phase 2 (HELIOS) for Wolfram syndrome, with positive Week 48 data announced in May 2025. AMX0114, an antisense oligonucleotide targeting calpain-2, entered Phase 1 in ALS with first participant dosing in April 2025.
Show full overview
Amylyx's near-term valuation is binary on the LUCIDITY topline readout expected Q3 2026: a successful outcome supports a U.S. NDA submission and a planned 2027 commercial launch, while a failure would eliminate the primary near-term revenue path. Five prior clinical trials in PBH—including the 28-day PREVENT Phase 2, which met its primary endpoint with a statistically significant 21% improvement in glucose nadir—form the evidentiary basis for Phase 3, but prior Phase 2 success has not protected the company before: PHOENIX failed despite encouraging Phase 2 data for ALS. The 10-K cautions that the PBH and congenital HI markets may be smaller than expected, adding commercial-size risk on top of trial outcome uncertainty.
See also: Healthcare · Drug Manufacturers - Specialty & Generic
From Amylyx Pharmaceuticals, Inc.'s most recent 10-K filing, extracted June 9, 2026.
Recent developments
updated Nov 4, 2026Recent Developments — Amylyx Pharmaceuticals, Inc.
Latest news
- NEWS Amylyx Pharmaceuticals to Host Investor Event at ObesityWeek® 2026 — fiscal.ai Nov 4, 2026 neutral
- NEWS Amylyx Pharmaceuticals to Participate in Upcoming November Investor Conferences — fiscal.ai Nov 3, 2026 neutral
- NEWS Amylyx Pharmaceuticals to Report Third Quarter 2026 Financial Results — fiscal.ai Nov 2, 2026
- NEWS Citigroup Maintains Buy on Amylyx Pharmaceuticals, Raises Price Target to $39 — benzinga Oct 15, 2026 positive
- NEWS Amylyx Pharma To Present Phase 3 Topline Data Highlighting Avexitide’s Efficacy And Safety At ObesityWeek 2026 Annual Me — benzinga Oct 6, 2026 positive
Latest item Nov 4, 2026 · Generated 2026-11-05T11:49:09Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- HIGHpipelineavexitide10-K Item 1A: 'We currently depend heavily on the success of avexitide, our most advanced product candidate, and AMX0035.'
- HIGHSupplierthird-party CMOs10-K Item 1: 'We rely, and expect to continue to rely for the foreseeable future, on third-party contract manufacturing organizations, or CMOs'
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Editorial policy
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. People who build TrendMatrix, or entities they control, may hold positions, long or short, in securities it covers, and may trade them at any time. Positions are not disclosed individually. Verdicts are generated by an automated model applied by the same rules to every covered stock, and are not adjusted for any position held by the people who build TrendMatrix. We do not accept payment from issuers for coverage.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
3 floor-breakers·1 ceiling hit
Quality below the gate floor. Component breakdown shows what dragged the score down.static
Volatile — 5.1% daily ATR makes tight stops impractical. Position-size conservatively.static
Technicals below the gate floor. Component breakdown shows what dragged the score down.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Engine safety override at $29.40: a dimension score below its floor triggers a hard block regardless of the otherwise-positive setup — overall score 5.2/10 and A.R:R 2.3:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 13%; Elevated put/call ratio: 1.82; Below-average business quality. Chart setup: No clear chart pattern; technical signals are mixed. Prior stop was $27.34. Score 5.2/10, moderate confidence.
Analyst target: $37.09 (+26.2% upside). Prior stop was $27.34. Stop-loss: $27.34.
Concentration risk — Pipeline: avexitide; Concentration risk — Supplier: third-party CMOs; Quality below floor (1.6 < 4.0).
Amylyx Pharmaceuticals, Inc. trades at a P/E of N/A (forward -27.0). TrendMatrix value score: 9.0/10. Verdict: Sell.
18 analysts rate AMLX, with a consensus score of 4.4/5. 11 analysts publish price targets averaging $43.
What does Amylyx Pharmaceuticals, Inc. do?Amylyx Pharmaceuticals is a clinical-stage company with no currently approved products, advancing therapies in...
Amylyx Pharmaceuticals is a clinical-stage company with no currently approved products, advancing therapies in endocrine and neurodegenerative diseases. The lead asset avexitide, a GLP-1 receptor antagonist for post-bariatric hypoglycemia, is in Phase 3 (LUCIDITY) with topline data expected Q3 2026. Additional pipeline: AMX0035 in Wolfram syndrome (Phase 2) and AMX0114 in ALS (Phase 1).